Stroke | Safety and efficacy of enterprise stenting for symptomatic atherosclerotic severe posterior circulation stenosis | springermedicine.com

Springer Medicine

Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Stroke | Research

Safety and efficacy of enterprise stenting for symptomatic atherosclerotic severe posterior circulation stenosis

Authors: Zhi-Long Zhou, Tian-Xiao Li, Liang-Fu Zhu, Li-Heng Wu, Min Guan, Zhen-Kai Ma, Yang-Hui Liu, Jin Qin, Bu-Lang Gao

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Purpose

To investigate the safety and efficacy of Enterprise stent angioplasty and risk factors for the prognoses in treating symptomatic severe posterior circulation atherosclerotic stenosis (SSPCAS).

Materials and methods

Patients with SSPCAS who were treated with the Enterprise stent angioplasty were retrospectively enrolled. The clinical data, peri-procedural complications, postoperative residual stenosis, in-stent restenosis and recurrent stroke at follow-up were analyzed.

Results

262 patients with 275 stenotic lesions treated with the Enterprise stent angioplasty were enrolled. The stenosis degree was reduced from 86.3 ± 6.2% before to 19.3 ± 5.4% after stenting. Complications occurred in 14 (5.3%) patients. Clinical follow-up was performed in 245 (93.51%) patients for 16.5 ± 7.3 months. During 1 year follow-up, 7 patients (2.9%) had recurrent symptoms, including 4 patients with stenting in the intracranial vertebral artery and 3 in the basilar artery. Imaging follow-up was conducted in 223 (85.11%) patients. In-stent restenosis was present in 35 patients (15.7%), with the restenosis rate of 26.4% (n = 23) in the intracranial vertebral artery, which was significantly (P < 0.001) greater than in the basilar artery (8.8%). Six patients (17.1%) with in-stent restenosis were symptomatic. The stenotic length was the only significant (P = 0.026 and 0.024, respectively) independent risk factor for 1 year stroke or death events and in-stent restenosis.

Conclusion

The Enterprise stent can be safely and efficaciously applied in the treatment of symptomatic severe posterior circulation atherosclerotic stenosis, with a relatively low rate of in-stent restenosis and recurrent stroke within 1 year. The stenotic length was the only significant independent risk factor for 1 year stroke or death events and in-stent restenosis.

1.

Labropoulos N, Nandivada P, Bekelis K. Stroke of the posterior cerebral circulation. Int Angiol. 2011;30:105–14.PubMed

2.

Zhang J, Zhang K, Jia B, Qi Z, Mo D, Ma N, et al. Risk of recurrence of symptomatic intracranial atherosclerosis in posterior circulation seen to be higher than that in anterior circulation in long-term follow-up. Front Neurol. 2020;11:574926.CrossRefPubMedPubMedCentral

3.

Kang K, Zhang Y, Shuai J, Jiang C, Zhu Q, Chen K, et al. Balloon-mounted stenting for icas in a multicenter registry study in China: a comparison with the weave/woven trial. J Neurointerv Surg. 2021;13:894–9.CrossRefPubMed

4.

Romano JG, Prabhakaran S, Nizam A, Feldmann E, Sangha R, Cotsonis G, et al. Infarct recurrence in intracranial atherosclerosis: results from the myriad study. J Stroke Cerebrovasc Dis. 2021;30:105504.CrossRefPubMed

5.

Ryu JC, Bae JH, Ha SH, Kwon B, Song Y, Lee DH, et al. In-stent restenosis and stented-territory infarction after carotid and vertebrobasilar artery stenting. BMC Neurol. 2023;23:79.CrossRefPubMedPubMedCentral

6.

Nouh A, Remke J, Ruland S. Ischemic posterior circulation stroke: a review of anatomy, clinical presentations, diagnosis, and current management. Front Neurol. 2014;5:30.CrossRefPubMedPubMedCentral

7.

Dashti SR, Park MS, Stiefel MF, McDougall CG, Albuquerque FC. Endovascular recanalization of the subacute to chronically occluded basilar artery: initial experience and technical considerations. Neurosurgery. 2010;66:825–31.CrossRefPubMed

8.

Caplan L, Wityk R, Pazdera L, Chang HM, Pessin M, Dewitt L. New England medical center posterior circulation stroke registry ii vascular lesions. J Clin Neurol. 2005;1:31–49.CrossRefPubMedPubMedCentral

9.

Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365:993–1003.CrossRefPubMedPubMedCentral

10.

Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the vissit randomized clinical trial. JAMA. 2015;313:1240–8.CrossRefPubMed

11.

Alexander MJ, Zauner A, Chaloupka JC, Baxter B, Callison RC, Gupta R, et al. Weave trial: final results in 152 on-label patients. Stroke. 2019;50:889–94.CrossRefPubMed

12.

Alexander MJ, Zauner A, Gupta R, Alshekhlee A, Fraser JF, Toth G, et al. The woven trial: wingspan one-year vascular events and neurologic outcomes. J Neurointerv Surg. 2021;13:307–10.CrossRefPubMed

13.

Gao P, Wang T, Wang D, Liebeskind DS, Shi H, Li T, et al. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: the cassiss randomized clinical trial. JAMA. 2022;328:534–42.CrossRefPubMedPubMedCentral

14.

Alexander MD, Rebhun JM, Hetts SW, Amans MR, Settecase F, Darflinger RJ, et al. Technical factors affecting outcomes following endovascular treatment of posterior circulation atherosclerotic lesions. Surg Neurol Int. 2017;8:284.CrossRefPubMedPubMedCentral

15.

Markus HS, Larsson SC, Dennis J, Kuker W, Schulz UG, Ford I, et al. Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the vist rct. Health Technol Assess. 2019;23:1–30.CrossRefPubMedPubMedCentral

16.

Tsivgoulis G, Katsanos AH, Magoufis G, Kargiotis O, Papadimitropoulos G, Vadikolias K, et al. Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2016;9:351–8.CrossRefPubMedPubMedCentral

17.

Fiorella D, Derdeyn CP, Lynn MJ, Barnwell SL, Hoh BL, Levy EI, et al. Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (sammpris). Stroke. 2012;43:2682–8.CrossRefPubMedPubMedCentral

18.

Nordmeyer H, Chapot R, Aycil A, Stracke CP, Wallocha M, Hadisurya MJ, et al. Angioplasty and stenting of intracranial arterial stenosis in perforator-bearing segments: a comparison between the anterior and the posterior circulation. Front Neurol. 2018;9:533.CrossRefPubMedPubMedCentral

19.

Shofti R, Tio F, Beyar R. Neointimal vascularization and intimal thickening in response to self-expanding stents: a swine model. Int J Cardiovasc Intervent. 2004;6:61–7.CrossRefPubMed

20.

Vajda Z, Schmid E, Guthe T, Klotzsch C, Lindner A, Niehaus L, et al. The modified bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the enterprise stent. Neurosurgery. 2012;70:91–101.CrossRefPubMed

21.

Zhao Y, Jin M, Liu Q, Liu D, Chen J, Du B. a long-term follow-up results of enterprise stent in treatment of severe symptomatic basilar artery atherosclerotic stenosis. Zhonghua Nei Ke Za Zhi. 2016;55:372–6.PubMed

22.

Yang S, Yao W, Siegler JE, Mofatteh M, Wellington J, Wu J, et al. Shortening door-to-puncture time and improving patient outcome with workflow optimization in patients with acute ischemic stroke associated with large vessel occlusion. BMC Emerg Med. 2022;22:136.CrossRefPubMedPubMedCentral

23.

Yan Y, Du L, He X, Huang Q, Pan Y, Xin T. Endovascular treatment of acute m1 occlusions due to underlying intracranial atherosclerotic severe stenosis. Chin Neurosurg J. 2022;8:22.CrossRefPubMedPubMedCentral

24.

Wang Y, Zhao X, Liu L, Soo YO, Pu Y, Pan Y, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in china: the Chinese intracranial atherosclerosis (cicas) study. Stroke. 2014;45:663–9.CrossRefPubMed

25.

Fujimoto M, Shobayashi Y, Takemoto K, Tateshima S, Vinuela F. Structural analysis for wingspan stent in a perforator model. Interv Neuroradiol. 2013;19:271–5.CrossRefPubMedPubMedCentral

26.

Cui R, Yan L, Kang K, Yang M, Yu Y, Mo D, et al. Long-term outcome of enterprise stenting for symptomatic icas in a high-volume stroke center. Front Neurol. 2021;12:672662.CrossRefPubMedPubMedCentral

27.

Groschel K, Schnaudigel S, Pilgram SM, Wasser K, Kastrup A. A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke. 2009;40:e340-347.CrossRefPubMed

28.

Li TX, Gao BL, Cai DY, Wang ZL, Zhu LF, Xue JY, et al. Wingspan stenting for severe symptomatic intracranial atherosclerotic stenosis in 433 patients treated at a single medical center. PLoS ONE. 2015;10:e0139377.CrossRefPubMedPubMedCentral

29.

Li A, Ye Z, Zhou W, Qin C. Short-term outcome of stenting with enterprise stents for symptomatic intracranial atherosclerotic disease at a single center. Interv Neuroradiol. 2022. https://doi.org/10.1177/15910199221133166.CrossRefPubMed

30.

Feng Z, Duan G, Zhang P, Chen L, Xu Y, Hong B, et al. Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis: an initial experience of 44 patients. BMC Neurol. 2015;15:187.CrossRefPubMedPubMedCentral

31.

Wilkinson IM. The vertebral artery extracranial and intracranial structure. Arch Neurol. 1972;27:392–6.CrossRefPubMed

32.

Wang X, Wang Z, Wang C, Ji Y, Ding X, Zang Y. Application of the enterprise stent in atherosclerotic intracranial arterial stenosis: a series of 60 cases. Turk Neurosurg. 2016;26:69–76.PubMed

Title: Safety and efficacy of enterprise stenting for symptomatic atherosclerotic severe posterior circulation stenosis
Authors: Zhi-Long Zhou
Tian-Xiao Li
Liang-Fu Zhu
Li-Heng Wu
Min Guan
Zhen-Kai Ma
Yang-Hui Liu
Jin Qin
Bu-Lang Gao
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Stroke
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01260-x

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties